Sarepta Presents the New Analyses and Functional Data of SRP-9001 in Multiple Studies for the Treatment of DMD at SRP-9001 Micro-dystrophin Day

 Sarepta Presents the New Analyses and Functional Data of SRP-9001 in Multiple Studies for the Treatment of DMD at SRP-9001 Micro-dystrophin Day

Shots:

  • The SRP-9001 program consists of 4 studies i.e., SRP-9001-301/103/102/101 that evaluates SRP-9001 in patients with DMD
  • In studies 101 & 102, SRP-9001-treated patients showed improvement in 8.6 & 2.9 points on NSAA over natural history cohort @3yrs. & 1yrs. after treatment & functional results from 103 study (cohort 1) showed 3.0 points improvement from baseline on NSAA @6mos., safety & tolerability is similar to previous reports
  • The company also presents the details of the P-III SRP-9001-301 (EMBARK) trial evaluates SRP-9001 vs PBO in 120 patients with DMD & therapy is being developed in collaboration with Roche. The 1EPs will assess the change in NSAA total score from baseline @52wks.

Click here to­ read full press release/ article | Ref: Sarepta | Image: BioSpace

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post